Literature DB >> 30852071

Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.

V Ricotti1, V Selby2, D Ridout3, J Domingos4, V Decostre5, A Mayhew6, M Eagle6, J Butler4, M Guglieri6, M Van der Holst7, M Jansen8, J J G M Verschuuren7, I J M de Groot8, E H Niks7, L Servais5, V Straub6, T Voit2, J Y Hogrel5, F Muntoni9.   

Abstract

The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Composite endpoint; Duchenne muscular dystrophy; Upper limb function and strength; forced vital capacity; peak expiratory flow; pulmonary function

Mesh:

Year:  2019        PMID: 30852071     DOI: 10.1016/j.nmd.2019.02.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  11 in total

1.  Pulmonary and upper limbs function in children with early stage Duchenne muscular dystrophy compared to their healthy peers.

Authors:  Numan Bulut; Güllü Aydın; İpek Alemdaroğlu-Gürbüz; Ayşe Karaduman; Öznur Yılmaz
Journal:  Braz J Phys Ther       Date:  2020-06-05       Impact factor: 3.377

2.  Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications.

Authors:  Alberto A Zambon; Megan A Waldrop; Roxane Alles; Robert B Weiss; Sara Conroy; Melissa Moore-Clingenpeel; Stefano Previtali; Kevin M Flanigan
Journal:  Neurology       Date:  2021-12-22       Impact factor: 9.910

3.  Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance.

Authors:  Kavya S Nair; Donovan J Lott; Sean C Forbes; Alison M Barnard; Rebecca J Willcocks; Claudia R Senesac; Michael J Daniels; Ann T Harrington; Gihan I Tennekoon; Kirsten Zilke; Erika L Finanger; Richard S Finkel; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2022

4.  Respiratory function and therapeutic expectations in DMD: families experience and perspective.

Authors:  Claudia Brogna; Simona Lucibello; Giorgia Coratti; Gianluca Vita; Valeria A Sansone; Sonia Messina; Emilio Albamonte; Francesca Salmin; Gloria Ferrantini; Elisa Pede; Chiara Consulo; Lavinia Fanelli; Nicola Forcina; Giulia Norcia; Marika Pane; Eugenio Mercuri
Journal:  Acta Myol       Date:  2020-09-01

5.  Upper and Lower Extremities in Duchenne Muscular Dystrophy Evaluated with Quantitative MRI and Proton MR Spectroscopy in a Multicenter Cohort.

Authors:  Sean C Forbes; Harneet Arora; Rebecca J Willcocks; William T Triplett; William D Rooney; Alison M Barnard; Umar Alabasi; Dah-Jyuu Wang; Donovan J Lott; Claudia R Senesac; Ann T Harrington; Erika L Finanger; Gihan I Tennekoon; John Brandsema; Michael J Daniels; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Radiology       Date:  2020-04-14       Impact factor: 11.105

Review 6.  Evaluation, Acceptance, and Qualification of Digital Measures: From Proof of Concept to Endpoint.

Authors:  Jennifer C Goldsack; Ariel V Dowling; David Samuelson; Bray Patrick-Lake; Ieuan Clay
Journal:  Digit Biomark       Date:  2021-03-23

7.  Genetic modifiers of respiratory function in Duchenne muscular dystrophy.

Authors:  Luca Bello; Grazia D'Angelo; Matteo Villa; Aurora Fusto; Sara Vianello; Beatrice Merlo; Daniele Sabbatini; Andrea Barp; Sandra Gandossini; Francesca Magri; Giacomo P Comi; Marina Pedemonte; Paola Tacchetti; Valentina Lanzillotta; Federica Trucco; Adele D'Amico; Enrico Bertini; Guja Astrea; Luisa Politano; Riccardo Masson; Giovanni Baranello; Emilio Albamonte; Elisa De Mattia; Fabrizio Rao; Valeria A Sansone; Stefano Previtali; Sonia Messina; Gian Luca Vita; Angela Berardinelli; Tiziana Mongini; Antonella Pini; Marika Pane; Eugenio Mercuri; Andrea Vianello; Claudio Bruno; Eric P Hoffman; Lauren Morgenroth; Heather Gordish-Dressman; Craig M McDonald; Elena Pegoraro
Journal:  Ann Clin Transl Neurol       Date:  2020-04-28       Impact factor: 4.511

8.  Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.

Authors:  Federica Trucco; Deborah Ridout; Mariacristina Scoto; Giorgia Coratti; Marion L Main; Robert Muni Lofra; Anna G Mayhew; Jacqueline Montes; Marika Pane; Valeria Sansone; Emilio Albamonte; Adele D'Amico; Enrico Bertini; Sonia Messina; Claudio Bruno; Deepak Parasuraman; Anne-Marie Childs; Vasantha Gowda; Tracey Willis; Min Ong; Chiara Marini-Bettolo; Darryl C De Vivo; Basil T Darras; John Day; Elizabeth A Kichula; Oscar H Mayer; Aledie A Navas Nazario; Richard S Finkel; Eugenio Mercuri; Francesco Muntoni
Journal:  Neurology       Date:  2020-10-16       Impact factor: 9.910

9.  Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.

Authors:  Laurent Servais; Eugenio Mercuri; Volker Straub; Michela Guglieri; Andreea M Seferian; Mariacristina Scoto; Daniela Leone; Erica Koenig; Navid Khan; Ashish Dugar; Xiaodong Wang; Baoguang Han; Dan Wang; Francesco Muntoni
Journal:  Nucleic Acid Ther       Date:  2021-11-17       Impact factor: 5.486

Review 10.  [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].

Authors:  Guenther Bernert; Andreas Hahn; Cornelia Köhler; Sascha Meyer; Ulrike Schara; Kurt Schlachter; Regina Trollmann; Maggie C Walter
Journal:  Nervenarzt       Date:  2020-11-19       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.